^
Association details:
| Biomarker: | AGGF1-PDGFRB fusion |
|---|---|
| Cancer: | Acute Lymphocytic Leukemia |
| Drug: | dasatinib (c-KIT inhibitor, Bcr-abl tyrosine kinase inhibitor, Src kinase inhibitor, EphA2 receptor antagonist, PDGFR β antagonist) |
| Direction: | Resistant |
Evidence:
Source:
Title:
PDGFRB mutation and tyrosine kinase inhibitor resistance in Ph-like acute lymphoblastic leukemia
Excerpt:
Ba/F3 cells expressing the mutant AGGF1-PDGFRB were significantly more resistant to ABL inhibitors imatinib (supplemental Figure 4), dasatinib, and nilotinib (Figure 2C-D), consistent with the patient’s clinical response to these agents at relapse.
DOI:
10.1182/blood-2017-11-817510
